Incidence and risk factors of anti‐tuberculosis drug induced liver injury (DILI): Large cohort study involving 4652 Chinese adult tuberculosis patients

Background and Aims Anti‐tuberculosis drugs remain as an important cause of drug‐induced liver injury (DILI) worldwide. Adverse drug reactions reduce the effectiveness of treatment. We aimed to determine the incidence and risk factors associated with anti‐tuberculosis DILI (ATDILI). Methods Using established criteria and causality assessment methods, risk factors for ATDILI were identified in a contemporary cohort and validated in another cohort prospectively. Independent determinants of ATDILI were identified using Cox regression analysis. Results In the derivation cohort (n = 3155), 170 (5.4%) developed ATDILI of which 27 (15.9%) developed jaundice; 9(5.3%) developed acute liver failure (ALF) and 3 died. Among HBsAg positive patients, 11/27 (40.7%) of ATDILI developed after 3 months of starting treatment. In addition, of 218 (6.9%) who developed raised alanine transferase (ALT) levels ≥3 times upper limit normal, 193 (88.5%) resolved and 25 (11.4%) progressed to DILI. Age (HR = 1.014, 95% CI: 1.005‐1.023), baseline ALT (HR = 1.014, 95% CI: 1.003‐1.024), haemoglobin (HR = 1.011, 95% CI: 1.002‐1.020) and HBsAg positivity (HR = 1.516, 95% CI: 1.004‐2.290) were independent risk factors for DILI. In the second cohort (n = 1497) of which 85 (5.7%) developed ATDILI. Age (HR = 1.029, 95% CI: 1.003‐1.056), baseline AST (HR = 1.036, 95% CI: 1.010‐1.062), previous TB treatment (HR = 3.894, 95% CI: 1.304‐11.625) and active drinking (HR = 3.624, 95% CI: 1.147‐11.454) were risk factors for developing jaundice. Conclusion Elevation of ALT of ≥3 × ULN during anti‐TB treatment resolves in the vast majority without developing serious consequences. In two cohorts involving 4652 patients, incidence of ALF and death because of ATDILI are low. Age, baseline ALT, haemoglobin and HBsAg positivity are risk factors for the development of DILI and these inform monitoring and management of these patients.